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Most routine practices for drugs-of-abuse testing do not include screening procedures for new 
psychoactive substances (NPS), despite their increasing diffusion, preventing clear knowledge of 
the real consumption of these new drugs in the screened populations. To make up for this 
shortcoming, a GC-MS method was developed for the simultaneous determination of 18 synthetic 
cathinones and one amphetamine-like compound in human urine. The sample preparation, was 
based on liquid–liquid extraction under alkaline condition followed by derivatization with 
trifluoroacetic anhydride. The separation of the 19 analytes was achieved in less than 10 minutes. 
The whole methodology was fully validated according to national and international guidelines. 
Selectivity, linearity range, identification (LOD) and quantitation (LOQ) limits, precision and 
accuracy were evaluated. For all the analytes the calibration curve was linear in the 100–1000 
ng/mL concentration range. The limits of detection ranged from 10 to 30 ng/mL and LOQs from 30 
to 100 ng/mL. Precisions were in the ranges 0.1–10.4%, and 1.0–12.1% for low (100 ng/mL) and 
high (1000 ng/mL) concentration, respectively. The accuracy, expressed as bias% was within ±20% 
for all the analytes. The present method was successfully applied to urine samples originating from 
autopsies, drug abuse/withdrawal controls, clinical investigations, roadside controls, driving re-
licensing and workplace testing. Seven urine samples were found positive for at least one NPS 
including butylone (4 cases), mephedrone (1 case) and 3-methylmethcathinone (1 case), while one 
sample turned out positive for 4-fluoroamphetamine. Traditional drugs-of-abuse, namely 
amphetamine, MDMA, ketamine, cocaine, and THC were also detected. The present method proved 
suitable for the detection of synthetic cathinones in urine samples from forensic cases. The range of 




Synthetic cathinones are sympathomimetic drugs related to cathinone, the major naturally occurring 
psychoactive component found in the leaves of the Catha edulis plant, commonly known as khat. 
They are sold under the misleading name of “legal highs”, “designer drugs”, “bath salts”, “research 
chemicals”, “plant food” or labeled “not for human consumption” [1,2].  Synthetic cathinones are 
sold in specialized shops known as “head shops” and in online shops. In particular, the internet 
market contributes significantly to their wide diffusion [2,3]. These compounds were initially 
synthesized to circumvent the existing laws on controlled substances, and/or to enhance the 
pharmacological activity of the more common amphetamines [4]. In addition to their specific 
stimulant and hallucinogenic properties, synthetic cathinones are abused for social and economic 
reasons, often serving as a replacement for MDMA, cocaine, and amphetamines [4,5]. The intake of 
synthetic cathinones generally occurs by snorting, injection, smoke or oral consume [3,6]. Their 
effects are euphoria, rush, alertness, talkativeness, sexual arousal, focused mind and overall positive 
feeling. The desired effects of synthetic cathinones occur within 30 to 45 min from administration 
and last from 1 to 3 h, followed by undesirable side effects that may persist from hours to days. The 
side effects range from neurological to cardiovascular and include anxiety, insomnia, fatigue, 
mydriasis, agitation, aggression, combative behavior and panic [1,7–9]. 
Synthetic cathinones represents a new trend in the recreational drug market and numerous cases of 
abuse, dependence, intoxication and deaths related to their consumption were described in the 
literature [1,5,10–13]. As a consequence, forensic and clinical laboratories worldwide are 
continuously requested to update their analytical procedures for the identification and quantification 
of these new drugs in various biological matrices. 
Specific enzyme immunoassay kits for the detection of synthetic cathinones have been recently 
developed [14,15], and are available on the market. However, these kits generally allow the 
identification of only a limited number of cathinones. Moreover, they have a relatively high cost 
and questionable performances in terms of sensitivity and specificity [16]. Several screening and 
confirmation methods based on MS and MS/MS techniques have been published for the 
determination of synthetic cathinones in urine [16,17] together with an increasing number of MS 
protocols using a multi-target approach [18–25]. In this study, we developed and validated a simple 
GC-MS method able to identify 18 cathinone-like compounds plus 4-fluoroamphetamine. The 
method was applied to authentic urine samples previously tested positive by Enzyme Multiplied 




3,4-dimethylmethcathinone, 3,4-methylenedioxypyrovalerone (MDPV), 4-fluoroamphetamine (4-
FA), 4-fluoromethcathinone, 4-methylethcathinone, 4-methylmethcathinone (4-MMC or 
Mephedrone), buphedrone, butylone (bk-MBDB), ethcathinone, methedrone, pentylone were 
obtained from Cayman Chemical (Ann Arbor, MI, USA); 1-naphyrone, 2-naphyrone, β-pentedrone, 
dimethylcathinone, ethylone (bk-MDEA), methylone (bk-MDMA), methcathinone and 
amphetamine esadeuterate were purchased from LGC Standards (Milan, Italy); 3-
methylmethcathinone was purchased from Bertin Pharna (Montigny-le-Bretonneux, France); 
diphenylamine was purchased from Sigma-Aldrich (Milan, Italy). The purity of the analytical 
standards was at least ≥95%. 
Stock standard solution were stored at −20°C until used. Working solutions were prepared at the 
final concentration of 10 µg/mL by dilution with methanol. 
Sodium hydroxide, tert-butylmethylether (TBME) and the derivatizing agent trifluoroacetic 
anhydride (TFAA) were purchased from Sigma-Aldrich (Milan, Italy). 
 
2.2. GC/MS characterization 
Full scan electron ionization mass spectra of the derivatization products of parent drugs were 
recorded from reference standards, in order to determine the most appropriate protocol for accurate 
and sensitive detection of the target analytes. According to 2002/657/EC requirements [26], the 
relative abundances of three characteristic ions (qualifier ions vs. target ion) along with the GC peak 
retention time were used for the positive identification of each target compound. 
 
2.3. Sample preparation 
Urine samples (2 mL) were added with 50 µL of internal standard mixture (amphetamine-d6 and 
diphenylamine) to yield a final concentration of 250 ng/mL and were subsequently alkalinized to 
pH 10−12 by adding few drops of NaOH 1N solution. Liquid–liquid extraction was performed by 
adding 10 mL of TBME under shaking in a multimixer for 10 min. After centrifugation at 2,200 
rpm for 3 min, the organic layer was transferred into a vial and dried under nitrogen at room 
temperature. The dry residue was allowed to react with 50 µL TFAA for 30 min at 65°C. After 
derivatization, the excess of TFAA was evaporated under a nitrogen stream at room temperature. 
The dry residue was re-dissolved in 50 µL of TBME and a 1 µL-aliquot was injected into the GC 
system with a split ratio of 10:1. 
 
2.4. Apparatus and methods 
The analyses were performed using a 6890N GC, combined with a 5975 inert Mass Selective 
Detector (Agilent Technologies, Milan, Italy) with electron ionization at 70eV. A 17 m fused-silica 
capillary column (J&W Scientific HP-5), with an inner diameter of 0.2 mm and a film thickness of 
0.33 mm was utilized for GC separation. Helium was employed as the carrier gas at a constant 
pressure of 31 psi. The GC oven temperature was set at 85°C and then raised to 110°C with a 12 
°C/min heating rate. The oven temperature was then raised to 300°C with a 30°C/min heating rate. 
The oven temperature was maintained at 300°C for 1 min. The total run time was 9.9 min. The GC 
injector and transfer line were maintained at 230°C and 250 °C respectively. Data were acquired in 
the selected-ion monitoring (SIM) mode using for each compound detection the diagnostic ions 
listed in Table 1. 
2.5. Validation 
The method was validated by investigating the following parameters: selectivity, linearity range, 
identification and quantitation limits (LOD and LOQ), precision, accuracy and carry over. The 
GC/MS methods validation was carried out according to national and international guidelines 
[27,28]. Blank urine specimens required for the method validation were obtained from ten different 
healthy volunteers (four females, six males). 
Selectivity.  Ten different blank urine samples were extracted, derivatized and analyzed as described 
above. The occurrence of possible interferences from endogenous substances or derivatization 
byproducts was tested by monitoring the selected-ion chromatograms, characteristic for each 
investigated compound, at the retention time interval expected for their elution. 
Linearity.  The linear calibration model was checked by analyzing (two replicates) negative urine 
samples spiked with standard solutions at five concentration levels (100, 200, 500, 750 and 1000 
ng/mL) for each analyte. The linear calibration parameters were obtained using the least squares 
regression method without weighting, due to the limited extension of the calibration range. 
Linearity was verified by the lack-of-fit test and the squared correlation coefficients (R2). 
Quantitative results from area counts were corrected using the IS signal. 
Limit of Detection (LOD).  The LOD was preliminarily estimated as the analyte concentration 
whose response provided a signal-to-noise (S/N) ratio of 3, as determined from the least abundant 
qualifier ion. The S/N ratio at the lowest concentration of the calibration range (100 ng/mL) was 
used to extrapolate the theoretical LOD. These calculated LOD values were then experimentally 
confirmed by analyzing spiked samples at LOD concentration for all analytes. The LOQ values 
were initially estimated as the analyte concentration whose response provided an S/N value equal to 
10. The practical LOQ was set at the lowest concentration of the calibration curves (100 ng/mL), 
which was positively tested for precision and accuracy requirements [29], as reported below. 
Precision and accuracy. Intra-assay precision (repeatability), expressed as percent variation 
coefficient (CV%) and accuracy evaluation (expressed as bias %), were assessed by extracting and 
analyzing ten replicates of negative urine samples spiked at two concentration levels (100 and 1000 
ng/mL). Standard criteria designated satisfactory assay precision when CV% values were below 
20% for concentrations of 100 ng/mL and below 15% for 1000 ng/mL. Satisfactory accuracy was 
achieved when the experimentally determined concentrations lied within ±20% from the expected 
values at 100 ng/mL and within ±15% at 1000 ng/mL. 
Carry-over. The background chromatographic profiles for each analyte were monitored during the 
analysis of blank urine sample injected after the chromatographic run of a spiked blank urine 
sample containing all the analytes at 1000 ng/mL concentration. The test was repeated five times in 
different periods. To assure the absence of carry-over, the signal to noise ratio (S/N) for each 
transition had to be lower than 3. 
 
3. Results and discussion 
3.1. GC/MS characterization 
All target analytes were easily characterized by different fragments. The SIM protocol developed 
(see Table 1) proved efficient in discriminating the interferences. 
The separation of the target analytes (as TFAA-derivatives) was achieved in less than 10 minutes. A 
GC/MS chromatogram obtained by adding up the SIM signals from a blank urine specimen fortified 
with 100 ng/mL of each compound is illustrated in Figure 1.  
 
3.2. Validation 
Selectivity.  Ten blank urines tested for the possible occurrence of endogenous interferences 
provided no quantifiable analyte peaks (i.e., S/N ratio less than 3) at the expected retention time for 
the target analytes. It was deduced that the method was selective for the compounds tested and free 
from positive interference from urine components and column bleeding. 
Linearity and evaluation of LOD and LOQ.  A calibration curve was built for all the investigated 
compounds in the interval 100−1000 ng/mL. The results of lack-of-fit tests and R2 values (ranging 
from 0.990 to 0.997) indicate good fit and linearity of all the calibration curves within the 
investigated concentration range (Table 2). Experimental LOD and calculated LOQ values (the 
latter extrapolated from S/N values of lowest concentration calibrator) are also reported in Table 2. 
Positive detection (S/N>3) of analytes at the approximate LOD concentrations was confirmed 
experimentally. LOD values lay between 10 and 30 ng/mL. 
Precision and accuracy.  
Intra-assay data on precision and accuracy are reported in Table 2. The results demonstrated 
satisfactory intra-assay precision at both low and high levels, as the percent variation coefficient 
(CV%) is lower than 15% for nearly all the analytes with the only exception of methylone (15.4% at 
100 ng/mL). Also the accuracy proved satisfactory at both low and high concentration levels, since 
bias% values fell within ±20% for all the analytes.  
Carry-over.  
The background chromatographic profiles monitored for each analyte during the analysis of blank 
urine injected after highly spiked samples, did not show the presence of any significant signal (i.e., 
the signal to noise ratio was always <3) at the retention times of the tested analytes. The presence of 
carry-over effect was therefore excluded. 
 
3.3.  Real Urine Samples 
Our laboratory protocol establishes for all urine samples that tested positive to amphetamines and 
methamphetamines by Enzyme Multiplied Immunoassay Technique (EMIT) to be confirmed for the 
presence of amphetamines, methamphetamines, and synthetic cathinones by means of a GC-MS 
method. The validated method presently described was applied to the authentic urine samples 
requiring confirmation for the latter class of stimulants, along with amphetamines and 
methamphetamines. The real samples were collected from either autopsies, drug abuse/withdrawal 
controls, clinical investigations, roadside controls, driving re-licensing, and workplace testing.  
Seven samples were found positive for at least one of the target analytes. Six positive samples 
originated from male subjects (age 20−31) while only one sample was from a female (aged 42). The 
final results are shown in Table 3. Synthetic cathinones were detected in six samples including 
butylone (4 cases; range 760−8390 ng/mL); mephedrone (1 case; 80550 ng/mL) and 3-
methylmethcathinone (1 case; 42700 ng/mL). In one case, the amphetamine-like compound 4-FA 
was found at a 850 ng/mL concentration. In five cases, the samples originated from roadside 
controls, while in two cases the sample was collected for either clinical investigation or during an 
autopsy. 
Besides cathinones, all tested samples were found positive to at least one traditional drug of abuse 
(and/or their metabolites) including amphetamine, MDMA, cocaine, ketamine, and THC. This 
finding confirms that NPS consumers are typically poly-abuses of both traditional and new drugs. It 
is noteworthy that all four urine samples that tested positive to butylone were also positive to 
MDMA. Even if a poly-abuse of MDMA and butylone was described in the literature, it cannot be 
excluded that butylone may have been unknowingly or unintentionally consumed after deceitful 
trade, as already reported in recent studies [30,31]. As a matter of fact, several cathinones including 
methylone, ethylone, and butylone are likely present as adulterants or in replacements for drugs sold 
as ecstasy [32–36], due to their psychoactive effects somehow similar to MDMA. In conclusion, it 
is not unlikely that most of the positive results that we found could be unexpected by the users 
themselves and can be attributed to the unaware intake of NPS. 
 
4. Conclusions 
Due to the wide range of NPS present in the black market, the chance to develop and implement 
effective analytical strategies to detect their presence in biological samples has become extremely 
challenging. The fast appearance of new NPS with distinctive chemical structures and metabolites 
makes the immunochemical screenings scarcely available, quite unspecific, and rapidly outdated, 
with the risk of underestimating the real consumption of these new drugs in the population and their 
potential involvement in traffic or work-related accidents. Among the various NPS classes, 
cathinones are among the most widely abused, especially by a percentage of electronic music events 
participants and discos regular clients [Ref.] 
In the present study, a GC-MS method for the simultaneous determination of a wide range of 
synthetic cathinones was developed and validated, with the objective of introducing its application 
within the regular routine task of confirming the results arising from immunoassay screening. The 
method showed good sensitivity, selectivity, and optimal linear response, together with good 
repeatability and accuracy for quantitative determinations in the concentration range useful for 
confirmation analysis. The analytical results on real samples confirm the diffusion of cathinones in 
the geographical region of our laboratory. In particular, the present study highlights the occurrence 
of poly-abuse of traditional and new drugs in the investigated population, irrespective of the 
deliberate or unaware intake of the latter class. The range of different circumstances under which 
the positive detection of cathinones may be of utmost importance makes the present method 
profitably applicable to urine samples collected from autopsies, drug abuse/withdrawal controls, 
clinical investigations, roadside controls, driving re-licensing, and workplace testing. 
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